As an Origination Partner at Flagship Pioneering, Molly Gibson, PhD, co-founded her first company, Generate:Biomedicines, in 2018, where she made her mark by developing models that design novel proteins—work that has already led to a Phase 3 asthma drug. Since then, she has gone on to co-found two additional companies: Expedition Medicines and Lila Biosciences. In this episode, Molly explains why the anticipated boom in AI-guided drug development hasn’t fully materialized and how she’s tackling the challenge by modeling complex chemistry to synthesize novel small molecules at Expedition Medicines. She also discusses building \"superintelligence\" and closed-loop systems in which AI can autonomously generate, test, and refine scientific ideas at Lila Biosciences.
Produced and hosted by Jonathan D. Grinstein, PhD
Audio mixed and mastered by Erick Ziegler
Brought to you by Inside Precision Medicine (SAGE Publishing)
","author_name":"Inside Precision Medicine"}